News
Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.
Chronic Rhinosinusitis With Nasal Polyps and Asthma: Understanding the Connection and Treatment Gaps
Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...
A survey of ENT clinicians reveals variability in managing chronic rhinosinusitis with nasal polyps, including steroid ...
A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges ...
Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 ...
Patients with CRSwNP have elevated levels of thymic stromal lymphopoietin (TSLP), Han said, which is a key driver of inflammation. Tezepelumab (Tezspire; Amgen, AstraZeneca) has been used to block ...
As for the ability of tissue SERPINB10 to be a predictive indicator of postop CRSwNP recurrence, although a link was seen between CRSwNP recurrence and tissue eosinophil percentage (odds ratio [OR ...
CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages. It can lead to breathing difficulties, ...
Hosted on MSN6mon
China’s NMPA approves GSK’s Nucala for CRSwNP treatmentOften associated with type 2 inflammation, CRSwNP is characterised by high levels of IL-5 in nasal polyp tissue and a tendency for nasal polyps to regrow post-surgery due to persistent inflammation.
The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively), which compared ...
Hosted on MSN4mon
GSK reports positive outcomes from two Phase III trials of ... - MSNUK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. The ANCHOR-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results